•
How to get started with making NPM Packages ?
Talks about NPM, Nodejs and Javascript Development
NS
Nimish Shah
Founder of Apogee Therapeutics
New York, New York
Overview
Nimish Shah is a biotech investor and executive based in New York, with a background in equity research and investment management. Notable career highlights include serving as a Partner at Venrock and Co-Founder and Board Director at Apogee Therapeutics, showcasing expertise in biotechnology and healthcare investments.
Currently, Nimish Shah is actively involved in investing in early-stage biotech companies within the medical devices, pharmaceuticals, and biotech sectors in New York City, leveraging skills in financial modeling and health economics to drive successful investment decisions.
Work Experience
Partner
2013 - Current
Venrock is a venture capital firm investing in technology and healthcare companies.
Co-Founder and Board Director
2021
Research Analyst
2010 - 2013
Healthcare analyst for Surveyor Capital, a market neutral equity fund part of the Citadel Investment Group.
Citadel is one of the world's leading alternative investment firms,pursuing long-term returns for preeminent public and private institutions
Raised $40,472.00 from Northstar Ventures.
Research Analyst
2007 - 2010
Equity Research - Coverage included specialty and generic pharmaceutical companies. Assumed primary coverage of generics sector prior to departure.
Credit Suisse Group is a financial services company that advises clients in all aspects of finance.
Senior Consultant
2006 - 2007
Developed and/or refined commercial strategies for global top 20 pharmaceutical and biotechnology companies.
Outcomes Research Intern
2004 - 2005
Conducted outcomes and health economic analysis to support the commercialization of $500mm - $1bn CNS product.
Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.
Raised $32,000,000,000.00 from Starboard Value.
Medical Information Associate
2002 - 2003
Supported commercialization of Novartis products by providing medical information to key opinion leaders.